Paper Details

  1. Home
  2. Paper Details

Hepatitis C virus treatment response to ledipasvir/sofosbuvir among patients coinfected with HIV and HCV: Real world data in a black population.

Author: BangaJaspreet, NagarakantiSandhya, NizamiSobia, PortillaMario, SlimJihad, SwaminathanShobha

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

Ledipavir/sofosbuvir (LDV/SOF) is a highly effective treatment for hepatitis C virus (HCV) infection, even in patients with HIV coinfection. A study of 107 Black patients with genotype 1 HCV and HIV coinfection found that LDV/SOF had a sustained virologic response rate of 93% at 12 weeks post-treatment completion. This suggests that LDV/SOF is an effective treatment option for this historically difficult-to-treat population.
Paper Details　
Original Abstract of the Article :
Treatment of hepatitis C virus (HCV) infection for patients with human immunodeficiency virus (HIV) has improved with direct acting antivirals. However, outcomes among Black persons treated with ledipasvir/sofosbuvir (LDV/SOF) may be inferior to non-Blacks. We assessed responses to LDV/SOF in a coho...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7440318/

データ提供：米国国立医学図書館（NLM）

Hepatitis C Treatment in a Black Population

The field of infectious disease research is constantly seeking new and effective therapies to combat a wide array of pathogens. This study focuses on the treatment of hepatitis C virus (HCV) infection, examining the effectiveness of ledipasvir/sofosbuvir (LDV/SOF) in a cohort of Black individuals coinfected with HIV. The researchers conducted a retrospective chart review of patients treated with LDV/SOF at three hospitals in Newark, NJ. Their findings shed light on the efficacy of this drug regimen in a historically underserved population.

High Efficacy in a Challenging Population

The study demonstrated a high sustained virologic response (SVR) rate of 93% in Black individuals coinfected with HIV who received LDV/SOF treatment. This finding suggests that LDV/SOF is a promising therapeutic option for this challenging patient population.

Hope for the Future

This study offers hope for improved treatment outcomes for Black individuals coinfected with HIV and HCV. The high SVR rate observed in this cohort suggests that LDV/SOF is a viable therapeutic option for this historically underserved population.

Dr. Camel's Conclusion

The pursuit of effective HCV treatment is a journey through a vast and complex desert, where challenges and disparities often arise. This study provides a beacon of hope, showcasing the effectiveness of LDV/SOF in a historically underserved population. The findings offer a glimpse into a brighter future, where effective treatments are available for all individuals, regardless of race or ethnicity.

Date :
  1. Date Completed 2020-03-23
  2. Date Revised 2022-12-07
Further Info :

Pubmed ID

32176039

DOI: Digital Object Identifier

PMC7440318

Related Literature

Article Analysis
・Side Effects of ledipasvir and sofosbuvir
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.